Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel

AUSTIN, Texas, July 15, 2021 -- (Healthcare Sales & Marketing Network) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metaboli... Biopharmaceuticals, Personnel Aeglea BioTherapeutics, pegzilarginase, Arginase 1 Deficiency
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news